Entrectinib FoundationOne liquid companion diagnostic - Foundation Medicine
Alternative Names: Entrectinib FoundationOne®Liquid CDx - Foundation MedicineLatest Information Update: 16 Sep 2024
At a glance
- Originator Foundation Medicine
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Non-small cell lung cancer; Solid tumours
Most Recent Events
- 16 Sep 2024 Launched for Non-small cell lung cancer (Diagnosis) in USA (unspecified route) prior to September 2024 (Foundation Medicine website, September 2024)
- 16 Sep 2024 Launched for Solid tumours (Diagnosis) in USA (unspecified route) prior to September 2024 (Foundation Medicine website, September 2024)
- 04 Jan 2023 Registered for Non-small cell lung cancer (Diagnosis) in USA (unspecified route)